The result of the meta-analysis showed that after the treatment, 54.7% (95%CI, 10.3 to 99.1%, very low-quality evidence) experienced adverse events, like acute kidney injury (19%, 5/27), constipation (15%, 4/27), increased alanine transaminase (ALT) (11%, 3/27), hyperglycemia (11%, 3/27), hypertension (11%, 3/27), pyrexia (11%, 3/27) [39], and anemia (3%, 2/77) [40]. The gene discussed is GPT; the disease is anemia (phenotype).